Skip to main content
NCBI home page
Oxford University Press logoLink to Oxford University Press
. 2023 Sep 23;115(2):401–409. doi: 10.1093/jleuko/qiad113

Single-cell transcriptomics reveal different maturation stages and sublineage commitment of human thymic invariant natural killer T cells

Kristina Maas-Bauer 1,2, Natalie Köhler 3,4, Anna-Verena Stell 5,#, Melissa Zwick 6,#, Swati Acharya 7, Anne Rensing-Ehl 8, Christoph König 9,10, Johannes Kroll 11, Jeanette Baker 12, Stefanie Koßmann 13, Amandine Pradier 14,15, Sisi Wang 16, Mylène Docquier 17,18, David B Lewis 19, Robert S Negrin 20,#,✉, Federico Simonetta 21,22,23,✉,3
PMCID: PMC10799303  PMID: 37742056

Abstract

Invariant natural killer T cells are a rare, heterogeneous T-cell subset with cytotoxic and immunomodulatory properties. During thymic development, murine invariant natural killer T cells go through different maturation stages differentiating into distinct sublineages, namely, invariant natural killer T1, 2, and 17 cells. Recent reports indicate that invariant natural killer T2 cells display immature properties and give rise to other subsets, whereas invariant natural killer T1 cells seem to be terminally differentiated. Whether human invariant natural killer T cells follow a similar differentiation model is still unknown. To define the maturation stages and assess the sublineage commitment of human invariant natural killer T cells during thymic development, in this study, we performed single-cell RNA sequencing analysis on human Vα24+Vβ11+ invariant natural killer T cells isolated from thymocytes. We show that these invariant natural killer T cells displayed heterogeneity, and our unsupervised analysis identified 5 clusters representing different maturation stages, from an immature profile with high expression of genes important for invariant natural killer T cell development and proliferation to a mature, fully differentiated profile with high levels of cytotoxic effector molecules. Evaluation of expression of sublineage-defining gene sets revealed mainly cells with an invariant natural killer T2 signature in the most immature cluster, whereas the more differentiated ones displayed an invariant natural killer T1 signature. Combined analysis with a publicly available single-cell RNA sequencing data set of human invariant natural killer T cells from peripheral blood suggested that the 2 main subsets exist both in thymus and in the periphery, while a third more immature one was restricted to the thymus. Our data point to the existence of different maturation stages of human thymic invariant natural killer T cells and provide evidence for sublineage commitment of invariant natural killer T cells in the human thymus.

Keywords: differentiation, human invariant natural killer T cells, iNKT, iNKT subsets, scRNAseq, thymic development

Human thymus contains different maturation stages of invariant natural killer T cells and facilitates sublineage commitment with invariant natural killer T2 properties in the most immature cells and an invariant natural killer T1 signature in the more differentiated clusters.

Human thymus contains different maturation stages and facilitates sublineage commitment of invariant natural killer T cells.

1. Introduction

Invariant natural killer T (iNKT) cells are a rare subset of innate lymphocytes representing less than 1% of the total lymphocyte population in both humans and mice. iNKT cells express a semi-invariant TCR, consisting of a Vα14Jα18 chain paired with a limited selection of beta chains in mice and Vα24Jα18 typically pairing with Vβ11 in humans, which recognize glycolipids presented in the context of the nonpolymorphic, histocompatibility complex (MHC)-like molecule CD1d.1,2 Upon stimulation, iNKT cells can promptly release a wide range of cytokines, allowing iNKT cells to exert a spectrum of pleiotropic functions, ranging from antitumor effects to immune-regulatory activity.3,4

Traditionally, thymic development of murine iNKT cells has been defined by different maturation stages based on the surface expression of CD24, CD44, and NK1.1: CD24hiCD44lo, NK1.1lo immature precursor iNKT cells (iNKT0 or iNKTp)5; CD24loCD44lo, NK1.1lo stage 1 iNKT cells; CD24loCD44hi, NK1.1lo stage 2 iNKT cells; and CD24loCD44hi, NK1.1hi stage 3 iNKT cells. Interestingly, these maturation stages have been associated with different functional properties, with stage 1 and 2 iNKT cells producing interleukin (IL) 4 and IL-10 and stage 3 iNKT cells producing interferon-γ, with limited proliferation potential compared to stage 1 and 2 iNKT cells.6–8 Such a model has been challenged by recent reports based on single-cell genomic analyses identifying the coexistence of different maturation iNKT stages in the murine thymus and also suggesting that populations with mixed characteristics exist.9

Partly opposed to the theory of different maturation stages, several studies indicated the existence of at least 3 terminally differentiated, murine iNKT sublineages, namely, Th-1–like iNKT (iNKT1), Th-2–like iNKT (iNKT2), and Th-17–like iNKT (iNKT17) cells.10,11 These subsets are characterized by the differential expression of the transcription factors promyelocytic leukemia zinc finger (PLZF), GATA binding protein 3 (GATA3), and T-bet and RAR-related orphan receptor gamma (RORγt) (iNKT1: PLZFlo, T-bet+, iNKT2: PLZFhi GATA3hi, iNKT17: PLZFintRORγt+)10,11; produce a unique cytokine profile10; and have special distribution in tissues.12 We recently demonstrated that distinct iNKT sublineages exert different functions, with iNKT2 and iNKT17 displaying immunoregulatory properties while iNKT1 exerts the strongest cytotoxic activity.13 Importantly, in contrast to what is observed in conventional T cells whose Th1, Th2, or Th17 lineage commitment takes place upon antigen encounter in the periphery, iNKT cell sublineage differentiation already takes place at the thymic level.10,11 Importantly, a recent single-cell report on thymic iNKT cells of prepubertal pigs showed big differences between murine and porcine iNKT cells.14 In this study, porcine iNKT cells were unexpectedly homogeneous, with 97% of cells expressing an iNKT2 genotype.

Despite the progress in understanding iNKT cell development and differentiation in animals, little is still known about human iNKT cell thymic development. Early studies studying human iNKT cell heterogeneity mainly focused on the analysis of peripheral blood.15,16 Studies investigating maturation processes of human iNKT cells at the thymic level based on such phenotypic heterogeneity have shown that, similarly to murine iNKT cells, the predominant iNKT cell population in neonatal human thymus includes CD4+CD161− iNKT cells, whereas CD4−CD161+ iNKT cells accumulate with age.17,18 Whether these subsets of human thymic iNKT cells correspond to distinct maturation stages is still unclear. Moreover, it is still unknown whether human iNKT cells commit at the thymic level toward any of the sublineage profiles reported in mice.

2. Methods

2.1. Human samples

Thymi were obtained after being removed from 5 newborn/infant donors undergoing cardiac surgery between 5 d and 13 mo of age for cardiac diseases without evidence of immunologic diseases. The analysis of human thymus samples obtained as surgical waste was reviewed and approved by Stanford University, Institutional Review Board (IRB Protocol #16877; directors Drs. David B. Lewis and Swati Acharya, Pediatric Cardiovascular Surgery, Stanford Children's Health) and the Ethics Committee of the University of Freiburg (CardioVascular BioBank approval #393/16, study protocol #10/20). Single-cell suspensions were obtained by mechanical dissociation, washed, cryopreserved in fetal calf serum and 10% DMSO, and stored in liquid nitrogen until use.

2.2. Preparation of thymic iNKT cells

Thymocytes were thawed at 37 °C in RPMI 1640 containing fetal calf serum (FCS) 30%, penicillin-streptomycin 1%, DNase I (10 μg/mL; Sigma), and heparin 20 U/mL. After washing, fluorescence-activated cell sorting (FACS) surface staining was performed on ice, after FC receptor blockage, using the following antibodies: Vα24 (clone C15, FITC, Beckman Coulter), Vβ11 (clone C21, APC, Beckman Coulter), CD3 (BV605, Biolegend), CD14 (APC Cy7, Biolegend or PE Cy7, Biolegend), CD19 (APC Cy7, Biolegend), and LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Invitrogen). CD3+, Vα24+, Vβ11+, CD14−, and CD19− live cells were FACS-sorted on a FACS Aria-III (BD Biosciences).

2.3. Single-cell RNA sequencing

Single-cell libraries were generated separately from FACS-sorted human thymic iNKT cells using the Chromium Controller Single-Cell Instrument and Chromium Single Cell 3′ Library & Gel Bead Kit v2 (donors 1, 2, and 3) and Chromium X instrument and Chromium Single Cell 3′ Library & Gel Bead Kit v3 (donors 4 and 5) (10× Genomics). Sample demultiplexing, barcode processing, alignment to the GRCh38 assembly of the human genome, and single-cell 3′ gene counting were performed using the Cell Ranger Suite versions 2.1 and 6.1.2. A total of 1,217 cells were sequenced, with 404,267 mean reads per cell and 1,250 (984 to 1,949) median genes per cell. The detailed metrics per sample are provided in Supplementary Table 1. Cells with unique gene counts <100 or >2,500, as well as cells with >10% of mitochondrial genes, were excluded from the analysis. Single-cell RNA sequencing (scRNA-seq) analysis was performed using the Seurat R package, version 4. Data integration was performed using the IntegrateData() function after identifying anchors using the FindIntegrationAnchors() function. Pseudotime analysis was performed using the Monocle3 package. iNKT sublineage-specific gene signatures were generated on murine iNKT in our previous work13 or extracted from the original description by Engel et al.11 Human orthologs were identified using the biomaRt version 2.46.3 package. The composite expression score for each iNKT sublineage gene signature was calculated using Seurat's AddModuleScore function. Previously published scRNA-seq data sets from human iNKT cells recovered from the peripheral blood (GSE12824319) were combined after downsampling to 600 cells (200 cells per donor, 3 donors) to match the thymic data given the very different number of cells contained in the two data sets.

3. Results and discussion

We performed scRNA-seq on human thymic Vα24+Vβ11+ iNKT cells FACS-sorted from thymi from 5 newborn/infant donors (Fig. 1A). After removing doublets (>2,500 gene counts), cells with lowest (<100) gene counts, and cells with high (>10%) mitochondrial gene content, 862 cells were retained for downstream analysis (Fig. 1A). Unsupervised Uniform Manifold Approximation and Projection (UMAP) analysis segregated human thymic iNKT cells into 5 clusters (Fig. 1B). Such distribution was conserved across the 5 samples originating from the 5 different donors (Supplementary Fig. 1A). Cluster 0 (C0) was the smallest cluster, representing on average 4.9% of total cells (Supplementary Fig. 1B). Differential expression analysis performed to identify genes preferentially expressed in each cluster revealed that iNKT cells in C0 were enriched for genes previously reported in mice to be associated with development of iNKT cell precursors, including SRY-box transcription factor 4 (SOX420) and special AT-rich sequence-binding protein 1(SATB121) (Fig. 1C). Cluster 1 (C1) was the biggest one, representing on average 50.4% of all thymic iNKT cells (Supplementary Fig. 1B), and expressed other genes involved in iNKT cell development, namely, lymphoid enhancing factor 1 (LEF122,23) and integral membrane protein 2A (ITM2A9,24) (Fig. 1C). SOX4, encoding the transcription factor important for the development of iNKT cells,20 was preferentially expressed in cluster 0 and, to a lesser extent, in C1 (Fig. 1D). SOX4 and LEF1 have been shown to be important transcription factors for iNKT cell development.20 LEF1 is a crucial transcription factor for iNKT cell proliferation,22,23 and two extensive studies of murine thymic iNKT cells showed that LEF1 and SOX4 are highly upregulated in NKT0 cells.9,24 ITM2a, a gene preferentially expressed in C1, was also highly upregulated in the NKT0 population in these analyses.9,24 ITM2A is a target gene of GATA3, a transcription factor involved in differentiation of murine iNKT cells, especially for the production of Th2 cytokines by iNKT cells.25 Cells in cluster 2 (C2) expressed relatively high levels of SOX4, lower than C0 and similar to C1, but expressed high levels of CD74 (Fig. 1C), a gene associated with T cell–T cell contact and involved with the class II major histocompatibility complex, which has recently been linked to the ST1 differentiation state.26 Cluster 3 (C3) represented the second largest cluster (on average 29.4%; Supplementary Fig. 1B) among thymic iNKT cells and expressed higher levels of genes associated with iNKT full differentiation such as killer cell lectin-like receptor B1 (KLRB1, encoding the surface molecule CD161; Fig. 1E), a molecule associated with effector function in several lymphocytic subsets27 (Fig. 1C). To note, C3 cells expressed higher levels of CD69 (Fig. 1C) transcript, encoding a surface molecule associated with an activated state in T cells28 and augmented cytotoxicity in NK cells.29,30 The highest levels of KLRB1 transcripts were expressed by cluster 4 (C4), a small cluster representing on average 8% of thymic iNKT cells (Supplementary Fig. 1B) that was significantly enriched in molecules involved in cytotoxic effector functions, namely, NKG7, encoding a protein essential for cytotoxic granule exocytosis in effector lymphocytes (Supplementary Fig. 2A), and GZMA and PRF1, encoding the cytotoxic effector molecules granzyme A and perforin, respectively (Supplementary Fig. 2B and C). Overall, the gene program of cells in C0 and, to a lesser extent, C1 and C2 is compatible with an earlier developmental stage with higher expression of genes involved in iNKT cell development and proliferation, whereas cells in C3 and C4 resembled murine mature iNKT cells at a later stage of differentiation, with an upregulation of molecules associated with an activated phenotype in C3 and high expression of genes responsible for effector functions in C4. Based on these data, we hypothesized that the 5 clusters could correspond to different stages of human iNKT development. To address this hypothesis, we performed a pseudotime analysis with C0 defined as the root. This analysis revealed a cell transition trajectory from C0 to C1, C3 and C4 (Fig. 2A). Along such trajectory, we observed a progressive downregulation of the genes encoding the transcription factors LEF1, SATB1, and SOX4 (Fig. 2B). This was mirrored by the upregulation of genes known to be involved in iNKT terminal differentiation (KLRB17,24) and production of cytotoxic molecules (GZMA), revealing a dynamic process of cells in C0 maturing to cells in C1 and C3, resulting in a cytotoxic phenotype of the differentiated cells in C4. Taking these findings together, we suggest that different maturation stages of iNKT cells exist in human thymus. These findings are in line with previously reported murine data showing that different maturation stages of iNKT cells are present at the thymic level.9,24

Fig. 1.

Fig. 1.

Open in a new tab

Single-cell transcriptomic analysis reveals heterogeneity of human thymic iNKT cells. (A) Schematic representation of the experimental pipeline. (B) UMAP plot of scRNA-seq data showing distinct clusters of human thymic iNKT cells. (C) Single-cell heatmap representing the 10 most highly differentially expressed genes in human thymic iNKT cell clusters. Expression for each gene is scaled (z-scored) across single cells. (D, E) Relative expression and normalized counts of SOX4 (D) and KLRB1 (E) in human thymic iNKT cell clusters.

Fig. 2.

Fig. 2.

Open in a new tab

Pseudotime analysis indicates ontological relationship between human thymic iNKT cell clusters. (A) UMAP plot of scRNA-seq data colored by pseudotime. (B) Single-gene normalized expression levels across the pseudotime trajectory. Cells are colored by pseudotime.

Murine iNKT cells have been shown to differentiate at the thymic level into 3 sublineages—namely, iNKT1, iNKT2, and iNKT17 cells—displaying different transcriptomic,11,24 epigenomic,11 and functional13 characteristics. We therefore investigated whether human thymic iNKT cells also displayed signs of sublineage commitment. To this aim, we generated subset-specific gene signatures for iNKT1, iNKT2, and iNKT17 based on human gene orthologs of genes we previously identified in single-cell transcriptomic analysis of murine thymic iNKT cells (Supplementary Table 1).13 We chose this strategy rather than looking at single markers, such as the genes encoding the transcription factors T-bet, PLZF, GATA3, and RORγt, because of the nonlinear correlation between gene transcript detected by scRNAseq and protein levels. Our analysis detected an enrichment in iNKT1 signature-expressing cells in C4 and, to a lesser extent, in C3 (Fig. 3A). Conversely, cells in C0 displayed an enrichment for iNKT2 signature-expressing cells (Fig. 3B). We did not identify any clear pattern of distribution of iNKT17 signature-expressing cells (Fig. 3C). To validate these results, we performed a similar analysis using the iNKT subset gene signatures originally reported by Engel and colleagues in their seminal study.11 This analysis confirmed the highest expression of the iNKT1 gene signature in C4 (Supplementary Fig. 3A). Similarly, it identified an enrichment in the iNKT2 gene signature in C0 (Supplementary Fig. 3B) and did not reveal any clearly defined expression of the iNKT17 signature across the cell subsets (Supplementary Fig. 3C). Collectively, our analysis identifies heterogeneity among thymic iNKT cells and clearly demonstrates the existence of a cluster of cells displaying a transcriptional profile corresponding to the one reported in murine iNKT1 cells. These results demonstrate for the first time, to our knowledge, that human iNKT cells undergo full differentiation in the thymus. Conversely, iNKT cells with an iNKT17 profile did not cluster in one specific region in the UMAP analysis. Thus, we cannot conclude that iNKT17 cells also exist in human thymus. As human iNKT cells that express RORγt and IL-17 have been described in peripheral blood,31 it is possible that they either differentiate in the periphery32 or emigrate directly after differentiation. In addition to these data, several studies suggest that CD69 expression of iNKT1 cells is responsible for thymic retention24,33 and that only iNKT2, iNKT17, and some iNKT1 subsets leave the thymus.24

Fig. 3.

Fig. 3.

Open in a new tab

Identification of human iNKT cells expressing an iNKT1 and iNKT2 signature. Normalized expression of iNKT1 (A), iNKT2 (B), and iNKT17 (C) signatures in thymic iNKT cells. Color intensity and violin plots represent the composite expression score of iNKT sublineage-specific gene sets as calculated using Seurat's AddModuleScore function.

To compare the distribution of the iNKT subsets identified in the thymus to the one they display in the periphery, we next performed a combined analysis of our data set with publicly available scRNA-seq data obtained on iNKT cells isolated from human peripheral blood19 (Fig. 3). The combined analysis identified 3 clusters (Fig. 4A). A first cluster (cluster 0′, C0′) was observed almost exclusively in the thymus, where it represented on average 5.5% of iNKT cells, while it was virtually absent in the peripheral blood (Fig. 4B). Conversely, clusters 1′ (C1′) and 2′ (C2′) were present at similar proportions in peripheral blood and thymus (Fig. 4B). In terms of gene expression, C0′ displayed a phenotype reminiscent of the aforementioned C0, with the highest levels of SOX4 (Fig. 4C and E) as well as LEF1 and SATB1 (Fig. 4E). Conversely, C2′ displayed in both peripheral blood and thymus a more differentiated phenotype associated with expression of KLRB1 (Fig. 4D and E), CD69, and GZMA (Fig. 4E). C1′ displayed an intermediate transcriptomic profile that differed depending on the tissue of origin, SOX4+KLRB1− in the thymus and SOX4−KLRB1+ in the peripheral blood (Fig. 4C, D, E). In conclusion, our analysis revealed the existence of a population of immature human iNKT cells exclusively present in the thymus and of a more differentiated one originating in the thymus that persists and becomes predominant in the peripheral blood.

Fig. 4.

Fig. 4.

Open in a new tab

Comparison of human iNKT cells from thymus and peripheral blood. (A) UMAP plot of scRNA-seq data showing distinct clusters of human iNKT cells from thymus and peripheral blood. (B) Stacked plots indicating the proportions of different iNKT cell clusters in samples from human thymus and peripheral blood. (C, D) Relative expression and normalized counts of SOX4 (C) and KLRB1 (D) in human iNKT cell clusters depending on the tissue origin. (E) Bivariable heatmap representing the percentage (circle size) and the intensity (circle color) of expression of genes reflecting iNKT cell development and differentiation depending on the cluster and the tissue origin.

Before iNKT subsets in mice were investigated, data suggested that iNKT cells are defined by their maturation stage.7,34 Later iNKT1, iNKT2, and iNKT17 cells were identified as fully differentiated cell populations.10,35 More recent reports performed scRNA-seq and showed with trajectory analysis that iNKT cells in the thymus differ in their maturation stage.9,24 Moreover, they showed that iNKT1 and iNKT2 cells consist of different subgroups and suggest a plasticity at least in iNKT0 and NKTp cells and in the more immature subgroups of iNKT2 cells.9,24 Thus, owing to these studies, it is now possible to reconcile the discovery of iNKT1, iNKT2, and iNKT17 subsets with the knowledge of different maturation stages of iNKT cells in the thymus, suggesting that iNKT2 cells display immature characteristics compared to iNKT1 and iNKT17 cells and probably function as a precursor for these subsets.9,24 Moreover, a recent study of thymic porcine iNKT cells also demonstrated that some iNKT2 cell subsets of prepubertal pigs had immature properties with an upregulation of LEF1 and SATB1 that is typical for immature iNKT cells.14 Intriguingly, these data are also in line with our findings that cells with an iNKT2 signature are present in the human thymus, yet appear with immature properties.

As the composition of iNKT cells is altered with aging36 and might differ among individuals, our analysis represents a snapshot of iNKT cell distribution at a very young age. Furthermore, the number of cells in our analysis is limited due to the paucity of iNKT cells in human thymus and the difficulties in accessing thymic tissue. This might especially limit our ability to detect minor cell subsets. We can therefore not exclude that other intermediate or fully differentiated states exist but have been missed by our analysis due to the limited number of cells.

To our knowledge, this is the first study investigating the transcriptomic differences of human thymic iNKT cells, with respect to iNKT maturation stages and cell subsets. Moreover, our data are in line with recent murine studies showing that iNKT cells with iNKT2 properties have immature characteristics and can give rise to terminally differentiated iNKT1 cells. Our work is a first step to a better understanding of human iNKT cell heterogeneity at the thymic level. Future studies will explore human iNKT subsets and decipher their function.

Supplementary Material

qiad113_Supplementary_Data
Click here for additional data file. (911.7KB, zip)

Acknowledgments

The authors thank Dr. Dhananjay Wagh at the Stanford Functional Genomics Facility and technicians at the iGE3 Genomics Platform, University of Geneva for their excellent technical assistance in the genomics analysis. Moreover, the authors thank FREEZE Biobank, Center for Biobanking, Medical Center and Faculty of Medicine, University of Freiburg and the CardioVascular BioBank (CVBB), Department for Cardiovascular Surgery of the University Heart Centre Freiburg–Bad Krozingen for assistance with sample processing and patient material storage, as well as the Lighthouse Core Facility at the Medical Center Freiburg and the Stanford Shared FACS Facility for assistance with flow cytometry and sorting.

Contributor Information

Kristina Maas-Bauer, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Center for Clinical Sciences Research Building, 269 W. Campus Drive, Stanford, CA 94305, United States; Department of Hematology, Oncology, and Stem Cell Transplantation, Medical Center—University of Freiburg, Faculty of Medicine, Hugstetter Str. 55, Freiburg 79106, Germany.

Natalie Köhler, Department of Hematology, Oncology, and Stem Cell Transplantation, Medical Center—University of Freiburg, Faculty of Medicine, Hugstetter Str. 55, Freiburg 79106, Germany; CIBSS—Centre for Integrative Biological Signalling Studies, University of Freiburg, Schänzlestr. 18, Freiburg 79104, Germany.

Anna-Verena Stell, Department of Hematology, Oncology, and Stem Cell Transplantation, Medical Center—University of Freiburg, Faculty of Medicine, Hugstetter Str. 55, Freiburg 79106, Germany.

Melissa Zwick, Department of Hematology, Oncology, and Stem Cell Transplantation, Medical Center—University of Freiburg, Faculty of Medicine, Hugstetter Str. 55, Freiburg 79106, Germany.

Swati Acharya, Sean N. Parker Center for Asthma and Allergy Research, Department of Medicine, Stanford University, 240 Pasteur Dr, Stanford, CA 94304, United States.

Anne Rensing-Ehl, Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, Breisacher Str. 115, Freiburg 79106, Germany.

Christoph König, Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, Breisacher Str. 115, Freiburg 79106, Germany; Faculty of Biology, University of Freiburg, Schänzlestr. 1, Freiburg 79104, Germany.

Johannes Kroll, Department of Cardiovascular Surgery, Heart Center Freiburg University, Hugstetter Straße 55, Freiburg 79106, Germany.

Jeanette Baker, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Center for Clinical Sciences Research Building, 269 W. Campus Drive, Stanford, CA 94305, United States.

Stefanie Koßmann, Department of Hematology, Oncology, and Stem Cell Transplantation, Medical Center—University of Freiburg, Faculty of Medicine, Hugstetter Str. 55, Freiburg 79106, Germany.

Amandine Pradier, Division of Hematology, Department of Oncology, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, Geneva 1205, Switzerland; Translational Research Center for Oncohematology, Department of Medicine, Faculty of Medicine, University of Geneva, Rue Michel-Servet 1, Geneva 1211, Switzerland.

Sisi Wang, Translational Research Center for Oncohematology, Department of Medicine, Faculty of Medicine, University of Geneva, Rue Michel-Servet 1, Geneva 1211, Switzerland.

Mylène Docquier, iGE3 Genomics Platform, University of Geneva, Rue Michel-Servet 1, Geneva 1211, Switzerland; Department of Genetics & Evolution, University of Geneva, Rue Michel-Servet 1, Geneva 1211, Switzerland.

David B Lewis, Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, Stanford University School of Medicine, 240 Pasteur Dr, Stanford, CA 94304, United States.

Robert S Negrin, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Center for Clinical Sciences Research Building, 269 W. Campus Drive, Stanford, CA 94305, United States.

Federico Simonetta, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Center for Clinical Sciences Research Building, 269 W. Campus Drive, Stanford, CA 94305, United States; Division of Hematology, Department of Oncology, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, Geneva 1205, Switzerland; Translational Research Center for Oncohematology, Department of Medicine, Faculty of Medicine, University of Geneva, Rue Michel-Servet 1, Geneva 1211, Switzerland.

Author contributions

F.S., K.M.-B., and R.S.N. conceived and designed the study; K.M.-B., N.K., M.Z., A.V.S., S.A., and F.S. performed the experiments; F.S. analyzed the data; F.S., K.M.-B., and R.S.N. contributed to the interpretation of results; K.M.-B., S.A., R.S.N., and F.S. wrote the manuscript; S.A., A.R.-E., C.K., J.K., J.B., A.P., M.D., and D.B.L. provided essential reagents and methods; R.S.N. and F.S. supervised the research. All authors read and approved the submitted version of the manuscript.

Supplementary material

Supplementary materials are available at Journal of Leukocyte Biology online.

Funding

This work was supported by grants from the National Institutes of Health (NIH) (National Heart, Lung, and Blood Institute, P01 HL075462, and the National Cancer Institute, R01 CA23158201, R.S.N.), the German Cancer Aid (Mildred Scheel Postdoctoral Fellowship, K.M.-B.), the Else-Kröner-Fresenius-Stiftung (2021_EKEA.131, K.M.-B. and 2019_A74, N.K.) and the Berta-Ottenstein Program (Faculty of Medicine, Freiburg University, K.M.-B.), the Swiss Cancer League (BIL KLS 3806-02-2016, F.S.), the American Society for Blood and Marrow Transplantation (New Investigator Award 2018, F.S.), the Geneva Cancer League LGC 20 11 (F.S.), the ChooseLife Foundation (F.S.), the Fondation Henriette Meyer (F.S.) and the Dubois-Ferriere-Dinu-Lipatti Foundation (F.S.), the German Research Foundation (DFG)—SFB-1479—Project ID: 441891347 (N.K.), and DFG under Germany’s Excellence Strategy—CIBSS—EXC 2189—Project ID: 390939984 (N.K.). Flow cytometry analysis for this project was conducted on instruments in the Stanford Shared FACS Facility purchased by using an NIH S10 Shared Instrumentation Grant (S10RR027431-01). Sequencing was performed on instruments in the Stanford Functional Genomics Facility, including the Illumina HiSeq 4000 purchased by using an NIH S10 Shared Instrumentation Grant (S10OD018220).

Data availability

The data sets generated for this study can be found in the Gene Expression Omnibus database (accession number GSE210956).

References

  • 1. Lantz O, Bendelac A. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. J Exp Med. 1994:180(3):1097–1106. 10.1084/jem.180.3.1097 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science. 1997:278(5343):1626–1629. 10.1126/science.278.5343.1626 [DOI] [PubMed] [Google Scholar]
  • 3. Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L. CD1d-restricted iNKT cells, the ‘Swiss-Army knife’ of the immune system. Curr Opin Immunol. 2008:20(3):358–368. 10.1016/j.coi.2008.03.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Crosby CM, Kronenberg M. Tissue-specific functions of invariant natural killer T cells. Nat Rev Immunol. 2018:18(9):559–574. 10.1038/s41577-018-0034-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Benlagha K, Kyin T, Beavis A, Teyton L, Bendelac A. A thymic precursor to the NK T cell lineage. Science. 2002:296(5567):553–555. 10.1126/science.1069017 [DOI] [PubMed] [Google Scholar]
  • 6. Gadue P, Stein PL. NK T cell precursors exhibit differential cytokine regulation and require itk for efficient maturation. J Immunol. 2002:169(5):2397–2406. 10.4049/jimmunol.169.5.2397 [DOI] [PubMed] [Google Scholar]
  • 7. Pellicci DG, Hammond KJ, Uldrich AP, Baxter AG, Smyth MJ, Godfrey DI. A natural killer T (NKT) cell developmental pathway iInvolving a thymus-dependent NK1.1(-)CD4(+) CD1d-dependent precursor stage. J Exp Med. 2002:195(7):835–844. 10.1084/jem.20011544 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Coquet JM, Chakravarti S, Kyparissoudis K, McNab FW, Pitt LA, McKenzie BS, Berzins SP, Smyth MJ, Godfrey DI. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc Natl Acad Sci U S A. 2008:105(32):11287–11292. 10.1073/pnas.0801631105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Krovi S H, Zhang J, Michaels-Foster MJ, Brunetti T, Loh L, Scott-Browne J, Gapin L. Thymic iNKT single cell analyses unmask the common developmental program of mouse innate T cells. Nat Commun. 2020:11(1):6238. 10.1038/s41467-020-20073-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Lee YJ, Holzapfel KL, Zhu J, Jameson SC, Hogquist KA. Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of iNKT cells. Nat Immunol. 2013:14(11):1146–1154. 10.1038/ni.2731 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Engel I, Seumois G, Chavez L, Samaniego-Castruita D, White B, Chawla A, Mock D, Vijayanand P, Kronenberg M. Innate-like functions of natural killer T cell subsets result from highly divergent gene programs. Nat Immunol. 2016:17(6):728–739. 10.1038/ni.3437 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Lee YJ, Wang H, Starrett GJ, Phuong V, Jameson SC, Hogquist KA. Tissue-specific distribution of iNKT cells impacts their cytokine response. Immunity. 2015:43(3):566–578. 10.1016/j.immuni.2015.06.025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Maas-Bauer K, Lohmeyer JK, Hirai T, Ramos TL, Fazal FM, Litzenburger UM, et al. Invariant natural killer T-cell subsets have diverse graft-versus-host-disease-preventing and antitumor effects. Blood. 2021:138(10):858–870. 10.1182/blood.2021010887 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Gu W, Madrid DMC, Joyce S, Driver JP. A single-cell analysis of thymopoiesis and thymic iNKT cell development in pigs. Cell Rep. 2022:40(1):111050. 10.1016/j.celrep.2022.111050 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med. 2002:195(5):625–636. 10.1084/jem.20011786 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med. 2002:195(5):637–641. 10.1084/jem.20011908 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Sandberg JK, Stoddart CA, Brilot F, Jordan KA, Nixon DF. Development of innate CD4+ alpha-chain variable gene segment 24 (Valpha24) natural killer T cells in the early human fetal thymus is regulated by IL-7. Proc Natl Acad Sci U S A. 2004:101(18):7058–7063. 10.1073/pnas.0305986101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Berzins SP, Cochrane AD, Pellicci DG, Smyth MJ, Godfrey DI. Limited correlation between human thymus and blood NKT cell content revealed by an ontogeny study of paired tissue samples. Eur J Immunol. 2005:35(5):1399–1407. 10.1002/eji.200425958 [DOI] [PubMed] [Google Scholar]
  • 19. Zhou L, Adrianto I, Wang J, Wu X, Datta I, Mi QS. Single-cell RNAseq analysis uncovers distinct functional human NKT cell sub-populations in peripheral blood. Front Cell Dev Biol. 2020:8:384. 10.3389/fcell.2020.00384 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Malhotra N, Qi Y, Spidale NA, Frascoli M, Miu B, Cho O, Sylvia K, Kang J. SOX4 controls invariant NKT cell differentiation by tuning TCR signaling. J Exp Med. 2018:215(11):2887–2900. 10.1084/jem.20172021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Kakugawa K, Kojo S, Tanaka H, Seo W, Endo TA, Kitagawa Y, Muroi S, Tenno M, Yasmin N, Kohwi Y, et al. Essential roles of SATB1 in specifying T lymphocyte subsets. Cell Rep. 2017:19(6):1176–1188. 10.1016/j.celrep.2017.04.038 [DOI] [PubMed] [Google Scholar]
  • 22. Berga-Bolaños R, Zhu WS, Steinke FC, Xue HH, Sen JM. Cell-autonomous requirement for TCF1 and LEF1 in the development of natural killer T cells. Mol Immunol. 2015:68(2):484–489. 10.1016/j.molimm.2015.09.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Carr T, Krishnamoorthy V, Yu S, Xue HH, Kee BL, Verykokakis M. The transcription factor lymphoid enhancer factor 1 controls invariant natural killer T cell expansion and Th2-type effector differentiation. J Exp Med. 2015:212(5):793–807. 10.1084/jem.20141849 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Baranek T, Lebrigand K, de Amat Herbozo C, Gonzalez L, Bogard G, Dietrich C, Magnone V, Boisseau C, Jouan Y, Trottein F, et al. High dimensional single-cell analysis reveals iNKT cell developmental trajectories and effector fate decision. Cell Rep. 2020:32(10):108116. 10.1016/j.celrep.2020.108116 [DOI] [PubMed] [Google Scholar]
  • 25. Kim PJ, Pai SY, Brigl M, Besra GS, Gumperz J, Ho IC. GATA-3 regulates the development and function of invariant NKT cells. J Immunol. 2006:177(10):6650–6659. 10.4049/jimmunol.177.10.6650 [DOI] [PubMed] [Google Scholar]
  • 26. Wang J, Adrianto I, Subedi K, Liu T, Wu X, Yi Q, Loveless I, Yin C, Datta I, Sant’Angelo DB, et al. Integrative scATAC-seq and scRNA-seq analyses map thymic iNKT cell development and identify Cbfβ for its commitment. Cell Discov. 2023:9(1):61. 10.1038/s41421-023-00547-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Takahashi T, Dejbakhsh-Jones S, Strober S. Expression of CD161 (NKR-P1A) defines subsets of human CD4 and CD8 T cells with different functional activities. J Immunol. 2006:176(1):211–216. 10.4049/jimmunol.176.1.211 [DOI] [PubMed] [Google Scholar]
  • 28. Sancho D, Gómez M, Sánchez-Madrid F. CD69 Is an immunoregulatory molecule induced following activation. Trends Immunol. 2005:26(3):136–140. 10.1016/j.it.2004.12.006 [DOI] [PubMed] [Google Scholar]
  • 29. Moretta A, Poggi A, Pende D, Tripodi G, Orengo AM, Pella N, Augugliaro R, Bottino C, Ciccone E, Moretta L. CD69-mediated Pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor alpha/beta. J Exp Med. 1991:174(6):1393–1398. 10.1084/jem.174.6.1393 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Clausen J, Vergeiner B, Enk M, Petzer AL, Gastl G, Gunsilius E. Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells. Immunobiology. 2003:207(2):85–93. 10.1078/0171-2985-00219 [DOI] [PubMed] [Google Scholar]
  • 31. Venken K, Jacques P, Mortier C, Labadia ME, Decruy T, Coudenys J, Hoyt K, Wayne AL, Hughes R, Turner M, et al. RORγt inhibition selectively targets IL-17 producing iNKT and γδ-T cells enriched in spondyloarthritis patients. Nat Commun. 2019:10(1):9. 10.1038/s41467-018-07911-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Wang H, Hogquist KA. CCR7 defines a precursor for murine iNKT cells in thymus and periphery. Elife. 2018:7:e34793. 10.7554/eLife.34793 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Nakayama T, Kasprowicz DJ, Yamashita M, Schubert LA, Gillard G, Kimura M, Didierlaurent A, Koseki H, Ziegler SF. The generation of mature, single-positive thymocytes in vivo is dysregulated by CD69 blockade or overexpression. J Immunol. 2002:168(1):87–94. 10.4049/jimmunol.168.1.87 [DOI] [PubMed] [Google Scholar]
  • 34. Watarai H, Sekine-Kondo E, Shigeura T, Motomura Y, Yasuda T, Satoh R, Yoshida H, Kubo M, Kawamoto H, Koseki H, et al. Development and function of invariant natural killer T cells producing T(h)2- and T(h)17-cytokines. PLoS Biol. 2012:10(2):e1001255. 10.1371/journal.pbio.1001255 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Hogquist K, Georgiev H. Recent advances in iNKT cell development. F1000Res. 2020:9:F1000 Faculty Rev-127. 10.12688/f1000research.21378.1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Papadogianni G, Ravens I, Dittrich-Breiholz O, Bernhardt G, Georgiev H. Impact of aging on the phenotype of invariant natural killer T cells in mouse thymus. Front Immunol. 2020:11:575764. 10.3389/fimmu.2020.575764 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

qiad113_Supplementary_Data
Click here for additional data file. (911.7KB, zip)

Data Availability Statement

The data sets generated for this study can be found in the Gene Expression Omnibus database (accession number GSE210956).

Articles from Journal of Leukocyte Biology are provided here courtesy of Oxford University Press

RESOURCES